$PHAR Pharming: Reports Positive Phase 2 Leniolisib Data in Genetic Immunodeficiencies Beyond APDS, With Improvements Across Multiple Disease Markers ? • Mean spleen volume fell 26.4% (n=11), lymph-node lesions shrank 33.7% (n=4), and lung gas-exchange capacity improved 8.0% (n=7). • No new safety signals; all treatment-related adverse events were Grade 1. All 12 study completers entered a three-year extension. • Results from a small, uncontrolled 13-patient study; separate Phase 2 CVID topline data expected in November. 14-OCT-2026 05:40 AM ET